Jan 22 (Reuters) - Klaria Pharma Holding AB (publ) KLAR.ST :
* KLARIA SIGNS EXCLUSIVE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTS WITH PURDUE PHARMA (CANADA) FOR THE EMERGENCY TREATMENT OF ANAPHYLACTIC REACTIONS (KL-01401)
* PURDUE PHARMA - TOTAL VALUE OF ALL MILESTONES ACHIEVABLE IS $55.2 MILLION OF WHICH PAYMENTS AND NEAR-TERM MILESTONES ARE $5.2 MILLION
* PURDUE PHARMA - KLARIA WILL RECEIVE MID-TO-UPPER SINGLE DIGIT ROYALTIES ON NET SALES
* PURDUE PHARMA - FURTHER TERMS OF AGREEMENTS GIVE KLARIA EXCLUSIVE MANUFACTURING RIGHTS TO SUPPLY GLOBAL MARKET WITH KL-01401
* PURDUE PHARMA - KLARIA AB HAS ALSO ADDED EPINEPHRINE TO ITS LICENSE AGREEMENT WITH UPPSALAGRUPPEN MEDICAL AB
* PURDUE PHARMA - IN LICENSE AGREEMENT, UPPSALAGRUPPEN WILL RECEIVE A FOUR PERCENT ROYALTY ON KLARIA'S NET INCOME FROM SALES OF KL-01401